202,030 Shares in Fulcrum Therapeutics, Inc. Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
FULC Stock | USD 4.00 0.27 6.32% |
About 53% of Fulcrum Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Fulcrum Therapeutics stock suggests that many investors are impartial at this time. The current market sentiment, together with Fulcrum Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Fulcrum Therapeutics stock news signals to limit their universe of possible portfolio assets.
Fulcrum |
202,030 Shares in Fulcrum Therapeutics, Inc. Purchased by Jacobs Levy Equity Management Inc. MarketBeat
Read at news.google.com
Fulcrum Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Fulcrum Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fulcrum Therapeutics Fundamental Analysis
We analyze Fulcrum Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulcrum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulcrum Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Fulcrum Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Fulcrum Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fulcrum Therapeutics stock to make a market-neutral strategy. Peer analysis of Fulcrum Therapeutics could also be used in its relative valuation, which is a method of valuing Fulcrum Therapeutics by comparing valuation metrics with similar companies.
Peers
Fulcrum Therapeutics Related Equities
BYSI | BeyondSpring | 1.18 | ||||
STOK | Stoke Therapeutics | 2.70 | ||||
PHAT | Phathom Pharmaceuticals | 3.88 | ||||
MIRM | Mirum Pharmaceuticals | 5.24 | ||||
RAPT | RAPT Therapeutics | 6.84 |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |